article

Drug Target Review – Issue #2 2015

Posted: 10 June 2015 | Drug Target Review

Included in this issue: Drug Discovery, Screening, Hit-to-Lead, Antibodies, Stem Cells, Kinases and much more…

DTR Issue 2 2015

In Issue #2 2015 of Drug Target Review:

  • FOREWORD: Academic drug discovery in neurodegeneration: a new approach to an ageing problem
    Dr Eric Karran, Director of Research, Alzheimer’s Research UK
  • DRUG DISCOVERY: A new dawn in academic and pharma collaboration – a UK perspective
    Justin Bryans, MRC Technology’s Centre for Therapeutics Discovery
  • IN-DEPTH FOCUS: SCREENING
    Featuring articles from Kenji Schorpp and Kamyar Hadian, Institute of Molecular Toxicology and Pharmacology, Sheraz Gul, Fraunhofer-IME SP and Horst Flotow, Singapore Screening Centre. Plus, Thermo Fisher Scientific’s Market and Product Line Manager Tarja Hirvensalo discusses screening and imaging solutions
  • HIT-TO-LEAD: From hype to hope: challenging the norm in lead discovery
    Andy Merritt, MRC Technology Centre for Therapeutics Discovery
  • ANTIBODIES: Developing antibody therapeutics
    David Matthews, MRC Technology
  • IN-DEPTH FOCUS: STEM CELLS
    With articles from Dennis Schade, Technical University of Dortmund, Arne Hansen, University Medical Center Hamburg-Eppendorf and DZHK, Boris Greber, Max Planck Institute for Molecular Biomedicine, and Ginika J. Jideofor and Jeff D. Newman, Cranfield Institute of Health
  • KINASES: Novel approaches to targeting protein tyrosine kinases
    Danielle McCullough and Dr Carol Trim, Canterbury Christ Church University

Issue #2 2015 is restricted to logged-in members. Login or subscribe free to read it.


Related topics

Send this to a friend